source
- Eli Lilly to acquire Merida Biosciences in near-$2.9 billion deal to expand immune-disease pipelineEli Lilly announced it will buy privately held Merida Biosciences, a company that has created a technology to target and break down malfunctioning antibodies that drive many autoimmune disorders.…
- US biotech edge erodes as China overtakes in trials and research, raising security concernsThe United States is losing its lead in biotech as China now conducts more clinical trials and publishes more natural‑science papers. China passed the U.S. six years ago in trial numbers and soon…